-
Grifols Partners with BARDA to Develop Treatment for Sulfur Mustard Ocular Injury
•
Grifols (BME: GRF; NASDAQ: GRFS), a Spanish biopharmaceutical company, has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to test investigational ocular surface immunoglobulin (OSIG) eye drops for their potential to treat ocular damage resulting from sulfur mustard exposure. BARDA, which is part of the Administration…
-
Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion
•
Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has announced the completion of a significant transaction where it sold a 20% stake in Shanghai RAAS Blood Products Co., Ltd (SHE: 002252) to Haier Group, a Chinese electronics and appliances conglomerate, for RMB 12.5 billion…
-
Grifols Sells 20% Stake in Shanghai RAAS to Haier Group for USD 1.8 Billion
•
Grifols (BME: GRF; NASDAQ: GRFS), a Spanish pharmaceutical company, has announced the formation of an alliance with Haier Group, a Chinese electronics and appliances giant. Under the agreement, Grifols will sell a 20% equity stake in Shanghai RAAS (SRAAS) for RMB 12.5 billion (USD 1.8 billion). Following the transaction, Grifols…
